Home › Companies › ADMA Biologics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ADMA Biologics, Inc.’s Form 8-K, filed June 2, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 2, 2026: 4 items on ADMA Biologics, Inc.’s Form 8-K, filed June 2, 2026: 4 passed (calculated).
Notable dissent: 1 director (11.0% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Rubric Capital (13F, 5.6%, as of September 30, 2026) · Caligan Partners (13F, 2.6%, as of September 30, 2026) · Nantahala Capital (13F, 1.2%, as of September 30, 2026)
Explore ADMA Biologics, Inc. in the interactive database Compare manager voting policies
These tallies are ADMA Biologics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 2, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Alison C. Finger | 156,849,830 | -- | -- | 19,376,842 | 23,040,875 | 89% | Passed (calculated) | — |
| Elect Director: Eduardo Rene Salas | 171,947,523 | -- | -- | 4,279,149 | 23,040,875 | 98% | Passed (calculated) | — |
| 2. The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and | 198,655,040 | 329,056 | 283,451 | -- | -- | 99.8% | Passed (calculated) | — |
| 3. The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Say-on-Pay") | 168,169,866 | 7,730,690 | 326,116 | -- | 23,040,875 | 96% | Passed (calculated) | — |
Source: ADMA Biologics, Inc., Form 8-K, filed with the SEC on June 2, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
357 asset managers disclosed a vote on at least one ADMA Biologics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect the following Class I directors for a term expiring at the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Alison C. Finger
ADMA Biologics, Inc.’s own tally for this item (“Elect Director: Alison C. Finger”): 156,849,830 for, 19,376,842 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 104 asset managers below reported 91,631,130 for, 10,396,856 withheld, 153 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 25,918,010 | 0 | 0 | 427,111 | For |
| Vanguard | 20,445,936 | 0 | 153 | 37,231 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 4,051,804 | Withhold |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 1,589,164 | Withhold |
| Nuveen | 0 | 0 | 0 | 1,439,853 | Withhold |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 1,167,273 | Withhold |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 329,728 | 0 | 0 | 187,370 | Mixed |
| AIG/SunAmerica | 496,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 364,267 | Withhold |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 0 | 0 | 292,066 | Withhold |
| Brighthouse | 75,298 | 0 | 0 | 202,333 | Mixed |
Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect the following Class I directors for a term expiring at the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Eduardo Rene Salas
ADMA Biologics, Inc.’s own tally for this item (“Elect Director: Eduardo Rene Salas”): 171,947,523 for, 4,279,149 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 104 asset managers below reported 99,796,742 for, 2,247,993 withheld, 39 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 26,345,121 | 0 | 0 | 0 | For |
| Vanguard | 20,483,281 | 0 | 39 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 4,051,804 | 0 | 0 | 0 | For |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 1,589,164 | Withhold |
| Nuveen | 1,439,853 | 0 | 0 | 0 | For |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 1,167,273 | 0 | 0 | 0 | For |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 329,728 | 0 | 0 | 187,370 | Mixed |
| AIG/SunAmerica | 496,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,267 | 0 | 0 | 0 | For |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Russell Investments | 292,066 | 0 | 0 | 0 | For |
| Brighthouse | 75,298 | 0 | 0 | 202,333 | Mixed |
Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 89.0% for (June 4, 2025 meeting) ▲ 6.6 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
ADMA Biologics, Inc.’s own tally for this item (“3. The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Say-on-Pay")”): 168,169,866 for, 7,730,690 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 26,345,121 | 0 | 0 | 0 | For |
| Vanguard | 20,483,296 | 20 | 2 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 4,051,804 | 0 | 0 | 0 | For |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 0 | 2,561,022 | 0 | 0 | Against |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,589,164 | 0 | 0 | 0 | For |
| Nuveen | 1,439,853 | 0 | 0 | 0 | For |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 1,167,273 | 0 | 0 | 0 | For |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 517,098 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 496,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,267 | 0 | 0 | 0 | For |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Russell Investments | 292,066 | 0 | 0 | 0 | For |
| Brighthouse | 277,631 | 0 | 0 | 0 | For |
Fund voting reports, all 103 managers: 99,153,394 for, 2,842,811 against, 48,567 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 13,687,181 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 11,738,761 | 0 | 0 | 0 | For |
| BlackRock | 9,326,781 | 3,111 | 0 | 0 | For |
| Nuveen | 6,203,477 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 5,830,605 | 0 | 0 | 0 | For |
| Caligan Partners LP | 4,109,865 | 0 | 0 | 0 | For |
| American Century | 3,968,259 | 0 | 0 | 0 | For |
| Invesco | 0 | 3,308,646 | 0 | 0 | Against |
| B Group, Inc. | 3,198,949 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,551,027 | 0 | 0 | 0 | For |
| Charles Schwab | 2,089,701 | 0 | 0 | 0 | For |
| Ranger Investment Management, L.P. | 2,055,615 | 0 | 0 | 0 | For |
| Vanguard | 2,010,052 | 0 | 0 | 0 | For |
| Northern Trust | 1,994,917 | 0 | 0 | 0 | For |
| Federated Hermes | 1,848,708 | 0 | 0 | 0 | For |
| Putnam | 1,802,412 | 0 | 0 | 0 | For |
| Fundsmith LLP | 0 | 1,649,493 | 0 | 0 | Against |
| Duquesne Family Office LLC | 1,545,610 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,501,886 | 0 | 0 | 0 | For |
| Point72 | 1,490,651 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 1,392,626 | 0 | 0 | 0 | For |
| MetLife Investment Management, LLC | 1,376,129 | 0 | 0 | 0 | For |
| National Philanthropic Trust | 0 | 0 | 0 | 0 | Not Voted |
| JUPITER ASSET MANAGEMENT LTD | 924,183 | 0 | 0 | 0 | For |
| Renaissance | 814,602 | 0 | 0 | 0 | For |
Institutional-manager reports, all 282 managers: 99,363,054 for, 6,072,612 against, 65,874 abstained, 1,199,338 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Prior year: 99.9% for (June 4, 2025 meeting) unchanged
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
ADMA Biologics, Inc.’s own tally for this item (“2. The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and”): 198,655,040 for, 329,056 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 104 asset managers below reported 101,996,205 for, 2 against, 48,567 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 26,345,121 | 0 | 0 | 0 | For |
| Vanguard | 20,483,316 | 2 | 2 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 4,051,804 | 0 | 0 | 0 | For |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,589,164 | 0 | 0 | 0 | For |
| Nuveen | 1,439,853 | 0 | 0 | 0 | For |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 1,167,273 | 0 | 0 | 0 | For |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 517,098 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 496,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,267 | 0 | 0 | 0 | For |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Russell Investments | 292,066 | 0 | 0 | 0 | For |
| Brighthouse | 277,631 | 0 | 0 | 0 | For |
Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 232,288,977 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 11.34% |
| 2 | Vanguard | 8.82% |
| 3 | Capital Group | 5.05% |
| 4 | State Street | 3.85% |
| 5 | Fidelity | 2.47% |
| 6 | TIAA | 1.74% |
| 7 | American Century | 1.53% |
| 8 | Invesco | 1.10% |
| 9 | Charles Schwab | 0.83% |
| 10 | T. Rowe Price | 0.68% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 5.89% |
| 2 | Capital Research Global Investors | 5.05% |
| 3 | BlackRock | 4.02% |
| 4 | Nuveen | 2.67% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
| 6 | Caligan Partners LP | 1.77% |
| 7 | American Century | 1.71% |
| 8 | Invesco | 1.42% |
| 9 | B Group, Inc. | 1.38% |
| 10 | T. Rowe Price | 1.10% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 36,830,774 | 15.86% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 20,854,669 | 8.98% | Form 13F, quarter ended March 31, 2026 |
| State Street | 14,084,205 | 6.06% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 6,247,242 | 2.69% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 5,005,481 | 2.15% | Form 13F, quarter ended March 31, 2026 |
| Invesco | 4,119,577 | 1.77% | Form 13F, quarter ended March 31, 2026 |
| Point72 | 3,309,657 | 1.42% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 2,803,530 | 1.21% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 232,288,977 shares outstanding, as reported by ADMA Biologics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ADMA Biologics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 357 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,753 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ADMA Biologics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 2, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADMA Biologics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ADMA Biologics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “ADMA Biologics (ADMA) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/adma-biologics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.